Myofacial PainPhase 4NCT02339662
Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain
A Phase 4 study testing Gabapentin and Amitriptyline in people with Myofacial Pain, run by Doron Aframian at 1 site in Israel.
Trial summary
The purpose of the study is comparing two drugs efficacy for the treatment of pain originates from masticatory muscles. The two drugs are - Amitriptlyne (amitriptyline) and Gabapentin (gabapentin), both of them are common use in for the treatment of chronic pain Methods - patient that is diagnosed as suffering from… Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Myofacial Pain
- What is being tested?
- Gabapentin and Amitriptyline
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteIsrael
- Study dates
- Feb 2015to Jan 2017
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients who suffer from chronic pain more than 3 months prior to arrival
- patients who are capable to reach all the visits in the clinic
- Not pregnant women
Who cannot join
- Patients with other types of non-muscle origin pain
- Patients without a clear diagnosis.
- Patients who are not originally designated to medication treatment (regardless experiment) for various reasons eg pregnancy.
- Patients who are not interested in medication.
- Patients who are not interested or unable to cooperate.
- Patients who suffer from chronic pain less than 3 months prior to arrival
- Pregnant women
Trial locations and contacts
1 site in 1 country.
Israel1 site, 1 recruiting
- Recruiting
Hadassah MO
Jerusalem
Doron J Aframian, MD,PhD, 97226776140, dorona@hadassah.org.il
About this study
The purpose of the study is comparing two drugs efficacy for the treatment of pain originates from masticatory muscles. The two drugs are - Amitriptlyne (amitriptyline) and Gabapentin (gabapentin), both of them are common use in for the treatment of chronic pain Methods - patient that is diagnosed as suffering from myofacial pain, will receive one of the medications above (Gabapentin or amitriptyline) for one month only, after which he will be invited to pain clinic for control. Two weeks after that, the patient will start taking the other drug for 1 month and then invited again to the department for recall and continue standard treatment . The patient can choose whether to continue medication with one of the drugs or stop this medication treatment. Total duration of the experiment is two and a half months.
Read the detailed description
Temporomandibular disorder is one of the main reasons for the pain and damage to the function in the head, jaws and neck (1,2) term is somewhat misleading because it includes two types of pain, one originates from the temporomandibular joint , and another originates mainly from the muscles of mastication - Myofacial pain (MFP). The last is the one we seek to explore the etiology of this pain is explained using a biological-psychological model, which reflects the complex interaction between physical factors, behavioral, social and emotional influences (3). The pain may last from weeks to many months; it is usually more severe on one side of the face, especially at pre-auricular area (front ear). Intensity of the pain is usually moderate; it has a squeezing, dull nature. It worsens during mouth opening and often causes opening restriction (5, 4). One can find trigger points where the pain is harsh and radiates to remote areas. Treatment is often integrated, multi-systemic and comprehensive (7, 6): physical therapy, behavioral therapy, night splints, Trigger point injection, and the use of drugs from different families are used to manage and treat MVP. Among the drugs that we use routinely are: Amitriptyline and nortriptyline from the family of tricyclic antidepressants (TAC's). These drugs were originally intended to treat depression and now days there primary use is to treat chronic pain from muscle origin, the use is in low doses of 10-35 mg /d, with no connection to the anti-depressive effect (8,9,10,11). . Gabapentin is gaba-amino buyic acid (GABA) analogue originally developed as an anti-epileptic (12). This drug is also used as a first treatment in neuropathic pain (13). A study published in 2007 by Kimos et al (14) suggested that using gabapentin at higher doses up to 4200 mg per day is a therapeutic option for myofacial pain. The authors prospectively examined the use of gabapentin versus placebo in myofacial pain over 12 weeks in 50 patients, of whom 36 completed the study, the results demonstrated improvement in any parameter. Another study conducted in our department and accepted for publication in journal of orafacail pain \& headache examined retrospectively gabapentin Vs amitriptyline with better results for gabapentin in more complex and widely spread disorder. To gabapentin side effect drug interactions profile better than amitriptyline (16). Moreover, gabapentin has no anticholinergic which usually limits the use of amitriptyline. Therefore, gabapentin may be an attractive alternative for the treatment of MFP. Our clinic use gabapentin routinely as second option after lack of response to amitriptyline. The aim of this study is to compare prospectively the efficacy amitriptyline in low doses up to 20 mg to gabapentin at low doses up to 900mg.
Patients over the age of 18 that will come to orofacial pain clinic in the department of Oral medicine, and which will be diagnosed as suffering from facial pain originating from chewing muscles (MVP) for at least three months, will be invited to participate in the study. The examination is the one we use routinely and includes: patient demographics: age, sex, marital status, occupation, and medical history. Pain characteristics includes : Location, duration, intensity (subjective), the nature of the pain, whether pain is prolonged or not, frequency and duration of attacks, disruption of sleep, quality of life and everyday functioning (work, company), whether the pain is accompanied by autonomic of systemic signs and whether the patient suffers from pain in the body outside the region head and neck. Patient will receive a questionnaire examining the accompanying emotional distress (AXIS II). Masticatory muscle involvement will be examined by palpation, load testing, restriction or non-limitation of mouth opening. All of which are routinely use in our department.
Patients will receive an explanation of the nature of the disease and possible treatments. Patients that would like to participate in the study, will sign a consent form, receive a pain questionnaire and start medication treatment which is acceptable in cases of myofacial pain. The drugs that will be used are: amitriptyline up to 20 mg and Gabapentin up to 900 mg. Patients with any side effects will call to receive instructions. After one month, patients will be invited to our clinic. A clinical examination, similar to one mention above will be performed with re-filling of the questionnaires. First medication treatment will discontinue and after two weeks will be replaced with the equivalent drug. Meaning patients that will begin with amitriptyline will continue with gabapentin (after two weeks break) and vice versa (cross over design). After another month patients will be invited to the clinic for further similar clinical examination and questionnaires fulfilling, then, if necessary patients will continue their preferred treatment. . All patients will give their consent to participate in the study.
Criteria for improvement include: 1. Intensity of pain according to VAS scale. 2. The frequency of the attacks. 3. The frequency of use of other drugs (for the treatment of chronic or acute pain). 4. Improving function - open mouth, free jaw movement. 5. Quality Health Index (AXIS II).
- Conditions
- Myofacial Pain
- Being tested
- Gabapentin, Amitriptyline
- Medical subject headings
- Facial Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GabapentinDrug
muscles pain treatment
AmitriptylineDrug
Also called alterolet
muscles pain treatment
| Study group | Role | What they receive |
|---|---|---|
| gabapentin | Active comparator | 900 mg per day total, 3 pills of 300mg. Receives: Drug: Gabapentin |
| amitriptyline | Active comparator | 20 mg total, 1pill Receives: Drug: Amitriptyline |
What is being measured
The primary outcome is the main question the study is designed to answer.
pain decrease
pain scale measuring
Measured: 6 weeks
Secondary outcomes (2)
The frequency of use of other drugs
breacking drugs registration
Measured: 6 weeks
Improving function - open mouth, free jaw movement
opening mouth measurement
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jan 2015 (estimated)
- Study startFeb 2015
- Primary completionJan 2016 (estimated)
- Study completionJan 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (13)Papers the sponsor has linked to this study.
- Other trials for Myofacial PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Doron Aframian
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Doron Aframian, Hadassah Medical Organization
- Investigators
- Doron J Aframian, DMD,PhD, Principal investigator, Hadassah Medical Organization
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02339662
- Sponsor's protocol ID
- gbvsam001-HMO-CTIL
- Status last verified
- Oct 2015
- First submitted
- 14 Dec 2014
- Last updated
- 20 Oct 2015
- Results posted
- No
- Data monitoring committee
- No
Publications
Tjakkes GH, Reinders JJ, Tenvergert EM, Stegenga B. TMD pain: the effect on health related quality of life and the influence of pain duration. Health Qual Life Outcomes. 2010 May 2;8:46. doi: 10.1186/1477-7525-8-46.
PubMed 20433769Maixner W, Diatchenko L, Dubner R, Fillingim RB, Greenspan JD, Knott C, Ohrbach R, Weir B, Slade GD. Orofacial pain prospective evaluation and risk assessment study--the OPPERA study. J Pain. 2011 Nov;12(11 Suppl):T4-11.e1-2. doi: 10.1016/j.jpain.2011.08.002. No abstract available.
PubMed 22074751Benoliel R, Svensson P, Heir GM, Sirois D, Zakrzewska J, Oke-Nwosu J, Torres SR, Greenberg MS, Klasser GD, Katz J, Eliav E. Persistent orofacial muscle pain. Oral Dis. 2011 Apr;17 Suppl 1:23-41. doi: 10.1111/j.1601-0825.2011.01790.x.
PubMed 21382137Kino K, Sugisaki M, Haketa T, Amemori Y, Ishikawa T, Shibuya T, Sato F, Amagasa T, Shibuya T, Tanabe H, Yoda T, Sakamoto I, Omura K, Miyaoka H. The comparison between pains, difficulties in function, and associating factors of patients in subtypes of temporomandibular disorders. J Oral Rehabil. 2005 May;32(5):315-25. doi: 10.1111/j.1365-2842.2004.01439.x.
PubMed 15842238Benoliel R, Eliav E, Sharav Y. Classification of chronic orofacial pain: applicability of chronic headache criteria. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Dec;110(6):729-37. doi: 10.1016/j.tripleo.2010.07.009.
PubMed 21112531Sherman JJ, Turk DC. Nonpharmacologic approaches to the management of myofascial temporomandibular disorders. Curr Pain Headache Rep. 2001 Oct;5(5):421-31. doi: 10.1007/s11916-001-0053-7.
PubMed 11560807Diamond S, Baltes BJ. Chronic tension headache--treated with amitriptyline--a double-blind study. Headache. 1971 Oct;11(3):110-6. doi: 10.1111/j.1526-4610.1971.hed1103110.x. No abstract available.
PubMed 4940167Pilowsky I, Hallett EC, Bassett DL, Thomas PG, Penhall RK. A controlled study of amitriptyline in the treatment of chronic pain. Pain. 1982 Oct;14(2):169-179. doi: 10.1016/0304-3959(82)90097-5.
PubMed 6757842Plesh O, Curtis D, Levine J, McCall WD Jr. Amitriptyline treatment of chronic pain in patients with temporomandibular disorders. J Oral Rehabil. 2000 Oct;27(10):834-41. doi: 10.1046/j.1365-2842.2000.00572.x.
PubMed 11065017Johannessen SI, Ben-Menachem E. Management of focal-onset seizures: an update on drug treatment. Drugs. 2006;66(13):1701-25. doi: 10.2165/00003495-200666130-00004.
PubMed 16978035Haviv Y, Zadik Y, Sharav Y, Benoliel R. Painful traumatic trigeminal neuropathy: an open study on the pharmacotherapeutic response to stepped treatment. J Oral Facial Pain Headache. 2014 Winter;28(1):52-60. doi: 10.11607/jop.1154.
PubMed 24482788Kimos P, Biggs C, Mah J, Heo G, Rashiq S, Thie NM, Major PW. Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial. Pain. 2007 Jan;127(1-2):151-60. doi: 10.1016/j.pain.2006.08.028. Epub 2006 Oct 9.
PubMed 17030096Chandra K, Shafiq N, Pandhi P, Gupta S, Malhotra S. Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial. Int J Clin Pharmacol Ther. 2006 Aug;44(8):358-63. doi: 10.5414/cpp44358.
PubMed 16961166
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain
- ClinicalTrials.gov ID
- NCT02339662
- Acronym / sponsor ID
- gbvsam001-HMO-CTIL
- Conditions
- Myofacial Pain
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Doron AframianUniversity, hospital or other
- Study start
- Feb 2015
- Primary completion
- Jan 2016 (estimated)
- Study completion
- Jan 2017 (estimated)
- First posted
- 15 Jan 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is comparing two drugs efficacy for the treatment of pain originates from masticatory muscles. The two drugs are - Amitriptlyne (amitriptyline) and Gabapentin (gabapentin), both of them are common use in for the treatment of chronic pain Methods - patient that is diagnosed as suffering from myofacial pain, will receive one of the medications above (Gabapentin or amitriptyline) for one month only, after which he will be invited to pain clinic for control. Two weeks after that, the patient will start taking the other drug for 1 month and then invited again to the department for recall and continue standard treatment . The patient can choose whether to continue medication with one of the drugs or stop this medication treatment. Total duration of the experiment is two and a half months.
Detailed description
Temporomandibular disorder is one of the main reasons for the pain and damage to the function in the head, jaws and neck (1,2) term is somewhat misleading because it includes two types of pain, one originates from the temporomandibular joint , and another originates mainly from the muscles of mastication - Myofacial pain (MFP). The last is the one we seek to explore the etiology of this pain is explained using a biological-psychological model, which reflects the complex interaction between physical factors, behavioral, social and emotional influences (3). The pain may last from weeks to many months; it is usually more severe on one side of the face, especially at pre-auricular area (front ear). Intensity of the pain is usually moderate; it has a squeezing, dull nature. It worsens during mouth opening and often causes opening restriction (5, 4). One can find trigger points where the pain is harsh and radiates to remote areas. Treatment is often integrated, multi-systemic and comprehensive (7, 6): physical therapy, behavioral therapy, night splints, Trigger point injection, and the use of drugs from different families are used to manage and treat MVP. Among the drugs that we use routinely are: Amitriptyline and nortriptyline from the family of tricyclic antidepressants (TAC's). These drugs were originally intended to treat depression and now days there primary use is to treat chronic pain from muscle origin, the use is in low doses of 10-35 mg /d, with no connection to the anti-depressive effect (8,9,10,11). . Gabapentin is gaba-amino buyic acid (GABA) analogue originally developed as an anti-epileptic (12). This drug is also used as a first treatment in neuropathic pain (13). A study published in 2007 by Kimos et al (14) suggested that using gabapentin at higher doses up to 4200 mg per day is a therapeutic option for myofacial pain. The authors prospectively examined the use of gabapentin versus placebo in myofacial pain over 12 weeks in 50 patients, of whom 36 completed the study, the results demonstrated improvement in any parameter. Another study conducted in our department and accepted for publication in journal of orafacail pain \& headache examined retrospectively gabapentin Vs amitriptyline with better results for gabapentin in more complex and widely spread disorder. To gabapentin side effect drug interactions profile better than amitriptyline (16). Moreover, gabapentin has no anticholinergic which usually limits the use of amitriptyline. Therefore, gabapentin may be an attractive alternative for the treatment of MFP. Our clinic use gabapentin routinely as second option after lack of response to amitriptyline. The aim of this study is to compare prospectively the efficacy amitriptyline in low doses up to 20 mg to gabapentin at low doses up to 900mg.
Patients over the age of 18 that will come to orofacial pain clinic in the department of Oral medicine, and which will be diagnosed as suffering from facial pain originating from chewing muscles (MVP) for at least three months, will be invited to participate in the study. The examination is the one we use routinely and includes: patient demographics: age, sex, marital status, occupation, and medical history. Pain characteristics includes : Location, duration, intensity (subjective), the nature of the pain, whether pain is prolonged or not, frequency and duration of attacks, disruption of sleep, quality of life and everyday functioning (work, company), whether the pain is accompanied by autonomic of systemic signs and whether the patient suffers from pain in the body outside the region head and neck. Patient will receive a questionnaire examining the accompanying emotional distress (AXIS II). Masticatory muscle involvement will be examined by palpation, load testing, restriction or non-limitation of mouth opening. All of which are routinely use in our department.
Patients will receive an explanation of the nature of the disease and possible treatments. Patients that would like to participate in the study, will sign a consent form, receive a pain questionnaire and start medication treatment which is acceptable in cases of myofacial pain. The drugs that will be used are: amitriptyline up to 20 mg and Gabapentin up to 900 mg. Patients with any side effects will call to receive instructions. After one month, patients will be invited to our clinic. A clinical examination, similar to one mention above will be performed with re-filling of the questionnaires. First medication treatment will discontinue and after two weeks will be replaced with the equivalent drug. Meaning patients that will begin with amitriptyline will continue with gabapentin (after two weeks break) and vice versa (cross over design). After another month patients will be invited to the clinic for further similar clinical examination and questionnaires fulfilling, then, if necessary patients will continue their preferred treatment. . All patients will give their consent to participate in the study.
Criteria for improvement include: 1. Intensity of pain according to VAS scale. 2. The frequency of the attacks. 3. The frequency of use of other drugs (for the treatment of chronic or acute pain). 4. Improving function - open mouth, free jaw movement. 5. Quality Health Index (AXIS II).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| gabapentin | Active comparator | Drug: Gabapentin900 mg per day total, 3 pills of 300mg. |
| amitriptyline | Active comparator | Drug: Amitriptyline20 mg total, 1pill |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients who suffer from chronic pain more than 3 months prior to arrival
- patients who are capable to reach all the visits in the clinic
- Not pregnant women
Key exclusion criteria (7 listed)
- Patients with other types of non-muscle origin pain
- Patients without a clear diagnosis.
- Patients who are not originally designated to medication treatment (regardless experiment) for various reasons eg pregnancy.
- Patients who are not interested in medication.
- Patients who are not interested or unable to cooperate.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Gabapentinmuscles pain treatment | Drug | gabapentin |
| AmitriptylineAlso: alteroletmuscles pain treatment | Drug | amitriptyline |
Primary outcome
pain decrease
Time frame: 6 weeks
pain scale measuring
2 secondary outcomes
The frequency of use of other drugs
Time frame: 6 weeks
Improving function - open mouth, free jaw movement
Time frame: 6 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2015.
- Background: PubMed 20433769Tjakkes GH, Reinders JJ, Tenvergert EM, Stegenga B. TMD pain: the effect on health related quality of life and the influence of pain duration. Health Qual Life Outcomes. 2010 May 2;8:46. doi: 10.1186/1477-7525-8-46.
- Background: PubMed 22074751Maixner W, Diatchenko L, Dubner R, Fillingim RB, Greenspan JD, Knott C, Ohrbach R, Weir B, Slade GD. Orofacial pain prospective evaluation and risk assessment study--the OPPERA study. J Pain. 2011 Nov;12(11 Suppl):T4-11.e1-2. doi: 10.1016/j.jpain.2011.08.002. No abstract available.
- Background: PubMed 21382137Benoliel R, Svensson P, Heir GM, Sirois D, Zakrzewska J, Oke-Nwosu J, Torres SR, Greenberg MS, Klasser GD, Katz J, Eliav E. Persistent orofacial muscle pain. Oral Dis. 2011 Apr;17 Suppl 1:23-41. doi: 10.1111/j.1601-0825.2011.01790.x.
- Background: PubMed 15842238Kino K, Sugisaki M, Haketa T, Amemori Y, Ishikawa T, Shibuya T, Sato F, Amagasa T, Shibuya T, Tanabe H, Yoda T, Sakamoto I, Omura K, Miyaoka H. The comparison between pains, difficulties in function, and associating factors of patients in subtypes of temporomandibular disorders. J Oral Rehabil. 2005 May;32(5):315-25. doi: 10.1111/j.1365-2842.2004.01439.x.
- Background: PubMed 21112531Benoliel R, Eliav E, Sharav Y. Classification of chronic orofacial pain: applicability of chronic headache criteria. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Dec;110(6):729-37. doi: 10.1016/j.tripleo.2010.07.009.
- Background: PubMed 11560807Sherman JJ, Turk DC. Nonpharmacologic approaches to the management of myofascial temporomandibular disorders. Curr Pain Headache Rep. 2001 Oct;5(5):421-31. doi: 10.1007/s11916-001-0053-7.
- Background: PubMed 4940167Diamond S, Baltes BJ. Chronic tension headache--treated with amitriptyline--a double-blind study. Headache. 1971 Oct;11(3):110-6. doi: 10.1111/j.1526-4610.1971.hed1103110.x. No abstract available.
- Background: PubMed 6757842Pilowsky I, Hallett EC, Bassett DL, Thomas PG, Penhall RK. A controlled study of amitriptyline in the treatment of chronic pain. Pain. 1982 Oct;14(2):169-179. doi: 10.1016/0304-3959(82)90097-5.
- Background: PubMed 11065017Plesh O, Curtis D, Levine J, McCall WD Jr. Amitriptyline treatment of chronic pain in patients with temporomandibular disorders. J Oral Rehabil. 2000 Oct;27(10):834-41. doi: 10.1046/j.1365-2842.2000.00572.x.
- Background: PubMed 16978035Johannessen SI, Ben-Menachem E. Management of focal-onset seizures: an update on drug treatment. Drugs. 2006;66(13):1701-25. doi: 10.2165/00003495-200666130-00004.
- Background: PubMed 24482788Haviv Y, Zadik Y, Sharav Y, Benoliel R. Painful traumatic trigeminal neuropathy: an open study on the pharmacotherapeutic response to stepped treatment. J Oral Facial Pain Headache. 2014 Winter;28(1):52-60. doi: 10.11607/jop.1154.
- Background: PubMed 17030096Kimos P, Biggs C, Mah J, Heo G, Rashiq S, Thie NM, Major PW. Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial. Pain. 2007 Jan;127(1-2):151-60. doi: 10.1016/j.pain.2006.08.028. Epub 2006 Oct 9.
- ebookLink provided by the sponsor.
Related trials for Myofacial Pain
Recruiting
Evaluation of the Effect of Adding Sodium Bicarbonate to Lidocaine in the Treatment of Myofascial Pain Syndrome
Myofacial Pain, Myofacial Pain Syndrome
Not yet recruiting
Focused Versus Multi-Target Trigger Point Injection for Chronic Myofascial Neck Pain
Myofacial Pain Syndrome, Chronic Neck Pain
Recruiting
Treatment Validation for Myofascial Pain
Chronic Low-back Pain (cLBP), Myofacial Pain
Not yet recruitingPhase 4
Lidocaine-prilocaine Cream as Analgesia for In-office Levator Muscle Trigger Point Injections
Myofacial Pain, Pelvic Pain
Recruiting
Dry Needling and Low-Level Laser Microcurrent Electrical Stimulation for Myofascial Pain Syndrome
Myofacial Pain Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Doron J Aframian, DMD,PhD principal investigator
Hadassah Medical Organization
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Gabapentin and Amitriptyline in people with Myofacial Pain, run by Doron Aframian at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Oct 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Doron J Aframian, DMD, PhD (972-2-677-6140, Dorona@hadassah.org.il), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
pain decrease (time frame: 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02339662, which also lists 13 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2015.